CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony‐stimulating factor (G‐CSF) for patients with aggressive non‐Hodgkin's lymphoma: a pilot study
CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony‐stimulating factor (G‐CSF) for patients with aggressive non‐Hodgkin's lymphoma: a pilot study
复制标题
CyclOBEAP（环磷酰胺、长春新碱、博来霉素、依托泊苷、阿霉素、泼尼松龙）联合粒细胞集落刺激因子 (G-CSF) 治疗侵袭性非霍奇金淋巴瘤患者：一项初步研究
DOI：
10.1034/j.1600-0609.2000.00250.x
复制
发表时间：
2000
影响因子：
3.1
通讯作者：
M. Hirano
中科院分区：
文献类型：
--
作者：
N. Niitsu;M. Okamoto;Yasuaki Kuraishi;S. Nakamura;F. Kodama;M. Hirano
摘要：我们进行了一项多机构合作研究，探讨第三代化疗 CyclOBEAP（环磷酰胺、长春新碱、博莱霉素、依托泊苷、多柔比星、泼尼松龙）联合粒细胞集落刺激因子（G-CSF）治疗侵袭性非霍奇金淋巴瘤（NHL）的有效性和安全性。受试者包括 60 岁或以下的侵袭性 NHL 患者，并使用国际预后指数 (IPI) 被诊断为低-中、高-中或高风险。 1997年5月至1998年3月期间共有24例患者入组，其中低中危病例9例，高中危病例13例，高危病例2例。尽管所有 24 名患者最初都参加了该研究，但随后排除了一名成人 T 细胞白血病/淋巴瘤病例。因此，最终评估了23个案例。治疗效果评估显示 20 名患者 (87%) 完全缓解。在这 20 名患者中，8 名是低中危病例（89%），12 名是高中危或高危病例（86%）。 2 名患者（8.7%）获得部分缓解。 2年生存率为91.3%，2年无病生存率为81.8%。 3级或以上不良反应为粒细胞减少（87%）、血小板减少（17.4%）和肝功能障碍（4.3%）。
Abstract: We conducted a multi‐institutional collaborative study to examine the usefulness and safety of third‐generation chemotherapy CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) combined with granulocyte colony‐stimulating factor (G‐CSF) in the treatment of aggressive non‐Hodgkin's lymphoma (NHL). Subjects included patients with aggressive NHL who were 60 yr of age or younger and had been diagnosed as having a low–intermediate, high–intermediate, or high risk using the International Prognostic Index (IPI). A total of 24 patients were enrolled in the study between May 1997 and March 1998, including 9 low–intermediate‐risk cases, 13 high–intermediate‐risk cases and 2 high‐risk cases. Although all 24 patients were originally enrolled in the study, one adult T‐cell leukemia/lymphoma case was subsequently excluded. Thus, in the end, 23 cases were evaluated. Evaluation of the efficacy of therapy revealed complete remission in 20 patients (87%). Of these 20 patients, 8 were low–intermediate‐risk cases (89%) and 12 were either high–intermediate‐ or high‐risk cases (86%). Partial remission was achieved in 2 patients (8.7%). The 2‐yr survival rate was 91.3%, and the 2‐yr disease‐free survival rate was 81.8%. Grade 3 or higher adverse reactions were granulocytopenia (87%), thrombocytopenia (17.4%) and liver dysfunction (4.3%).
登录
查看更多内容
影响因子：
11.2
作者：
P. Carbone;H. Kaplan;K. Musshoff;D. Smithers;M. Tubiana
通讯作者：
P. Carbone;H. Kaplan;K. Musshoff;D. Smithers;M. Tubiana
ProMACE-CytaBOM 治疗非霍奇金淋巴瘤的不利组织学：西南肿瘤小组的一项全组研究。
DOI：
10.1200/jco.1990.8.12.1951
发表时间：
1990
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Miller,TP;Dahlberg,S;Weick,JK;Files,JC;Eyre,HJ;Pendergrass,KB;Fisher,RI
通讯作者：
Fisher,RI
影响因子：
158.5
作者：
GORDON, LI;HARRINGTON, D;OCONNELL, M
通讯作者：
OCONNELL, M
影响因子：
45.3
作者：
KWAK, LW;HALPERN, J;HORNING, SJ
通讯作者：
HORNING, SJ
影响因子：
158.5
作者：
FISHER, RI;GAYNOR, ER;MILLER, TP
通讯作者：
MILLER, TP